Inovio Pharmaceuticals, Inc. — Q2 2014 Form 10-Q
Business context and period: The filing covers the quarter and six months ended June 30, 2014. Inovio is developing DNA-based vaccines and immune therapies, including electroporation delivery technology. It had no approved human products and reported no product-sales revenue; revenue came from collaborations, grants, and government contracts. The interim financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $3.80 million | $0.79 million | $6.16 million | $2.24 million |
| Research and development expense | $9.61 million | $4.41 million | $17.83 million | $9.53 million |
| General and administrative expense | $4.35 million | $3.05 million | $8.48 million | $6.02 million |
| Operating loss | $10.15 million | $5.67 million | $20.15 million | $12.31 million |
| Net loss attributable to Inovio | $10.71 million | $10.85 million | $21.53 million | $19.70 million |
| Basic loss per share | $0.18 | $0.24 | $0.37 | $0.47 |
| Cash used in operations | Not presented separately | Not presented separately | $13.71 million | $10.55 million |
At June 30, cash and cash equivalents were $88.54 million and short-term investments were $20.32 million. Management reported cash, short-term investments, and restricted cash of approximately $109.0 million, working capital of $101.3 million, and an accumulated deficit of $317.3 million. Total liabilities were $19.88 million; the filing presents no conventional interest-bearing debt balance. Management believed cash and short-term investments would fund planned working-capital needs through the end of 2017.
Changes versus prior comparable periods
- Q2 revenue rose to $3.80 million from $0.79 million, primarily because of revenue under the 2013 Roche collaboration. Six-month revenue increased to $6.16 million from $2.24 million.
- R&D expense approximately doubled year over year in both the quarter and six-month period, reflecting Roche-related work and biologics manufacturing, clinical and device development, increased staffing, and higher stock-based compensation.
- Operating losses widened, while Q2 net loss was slightly lower than the prior-year quarter. The year-over-year net-loss comparison was affected by warrant fair-value changes: a $0.82 million gain in Q2 2014 versus a $3.20 million loss in Q2 2013.
- Cash and short-term investments increased substantially from December 31, 2013, primarily due to financing and warrant and option exercises. The March 2014 public offering generated approximately $59.2 million net; six-month financing cash flow was $70.8 million.
Outlook, commentary, and risks
- No specific revenue or earnings guidance was provided. Management expected substantial operating losses to continue as it funds research, preclinical work, clinical trials, and regulatory activities; it said product revenue was not expected for at least several years.
- The Roche agreement covers co-development of prostate-cancer and hepatitis B DNA immunotherapies, with potential development, regulatory, and commercial payments of up to $412.5 million and tiered royalties. No event-based payments or milestones were achieved in the periods presented. In Q2, $3.1 million of revenue was recognized under the agreement.
- In May, subsidiary VGX Animal Health agreed to sell animal-health assets for $2.0 million in staged cash payments and a 20% interest in Plumbline Life Sciences. No receivable was recorded because collection was uncertain.
- The company entered an 11.5-year office lease; future minimum operating-lease payments totaled $14.05 million. The filing also reports no material legal proceedings.
- Principal risks include ongoing losses and future financing needs; clinical, manufacturing, and regulatory uncertainty; dependence on collaborators and government funding; competition; and intellectual-property and product-liability risks. Management cautioned that actual results may differ materially from forward-looking statements.
- A 4-for-1 reverse stock split took effect June 5, 2014; reported share data were retrospectively adjusted. Disclosure controls were reported effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether operating cash burn and planned R&D spending remain consistent with management’s stated runway through 2017.
- Roche collaboration revenue recognition, remaining deferred revenue, and progress toward milestones and clinical development.
- Clinical-trial results, timelines, manufacturing capacity, and regulatory progress for the company’s principal candidates.
- Potential dilution from future equity financing, outstanding options and warrants, and the effects of the reverse split.
- Collection and terms of the Plumbline consideration, and continuing obligations and costs associated with the long-term lease.
- Changes in warrant fair values, which materially affected period-to-period reported earnings and are based partly on valuation assumptions.